Airspace Dimension Assessment with Nanoparticles (AiDA) in Comparison to Established Pulmonary Function TestsShow others and affiliations
2022 (English)In: International Journal of Nanomedicine, ISSN 1176-9114, E-ISSN 1178-2013, Vol. 17, p. 2777-2790Article in journal (Refereed) Published
Abstract [en]
Background: Airspace Dimensions Assessment with nanoparticles (AiDA) is a new method for non-invasive measurement of pulmonary distal airspaces. The aim of this study was to compare AiDA measurements with other pulmonary function variables to better understand the potential of AiDA in a clinical context. Methods: AiDA measurements and pulmonary function tests were performed in 695 subjects as part of the Swedish CArdioPulmonary bioImage Study. The measurement protocol included spirometry, measurement of diffusing capacity of carbon monoxide, oscillometry and pulmonary computed tomography. AiDA indices were compared to all other pulmonary examination measurements using multivariate statistical analysis. Results: Our results show that AiDA measurements were significantly correlated with other pulmonary function examination indices, although covariance was low. We found that AiDA variables explained variance in the data that other lung function variables only influenced to a minor extent. Conclusion: We conclude that the AiDA method provides information about the lung that is inaccessible with more conventional lung function techniques. © 2022 Petersson-Sjögren et al.
Place, publisher, year, edition, pages
Dove Medical Press Ltd , 2022. Vol. 17, p. 2777-2790
Keywords [en]
aerosol nanoparticles, airspace dimension assessment with nanoparticles, COPD diagnostics, distal airspaces, respiratory diagnostics with nanoparticles, carbon monoxide, nanoparticle, diagnostic imaging, human, lung, lung function test, x-ray computed tomography, Humans, Nanoparticles, Respiratory Function Tests, Tomography, X-Ray Computed
National Category
Nano Technology
Identifiers
URN: urn:nbn:se:ri:diva-59870DOI: 10.2147/IJN.S360271Scopus ID: 2-s2.0-85133256379OAI: oai:DiVA.org:ri-59870DiVA, id: diva2:1685107
Note
Funding details: University Hospitals, UH; Funding details: VINNOVA; Funding details: Svenska Forskningsrådet Formas, 2018-00693; Funding details: Lunds Universitet; Funding details: Hjärt-Lungfonden, 2017-0644, 2018-0483, 2020-0855; Funding details: Linköpings Universitet, LiU; Funding details: Karolinska Institutet, KI; Funding details: Knut och Alice Wallenbergs Stiftelse; Funding details: Stockholms Läns Landsting; Funding details: Vetenskapsrådet, VR, 2021-03265; Funding details: Umeå Universitet; Funding details: Sahlgrenska Universitetssjukhuset, SU; Funding details: Göteborgs Universitet; Funding details: Forskningsrådet om Hälsa, Arbetsliv och Välfärd, FORTE, 2017-00690; Funding details: Uppsala Universitet; Funding details: Skånes universitetssjukhus, SUS; Funding text 1: Open access funding provided by Lund University. This work was supported by the Swedish Heart and Lung foundation (Grant No 2017-0644, Grant No 2018-0483 and Grant No 2020-0855), the Swedish Research Council for Health, Working Life and Welfare (Grant No 2017-00690), Swedish Research Council for Environmental, Agricultural Sciences and Spatial Planning, FORMAS (Grant No: 2018-00693), NanoLund, and The Swedish Research Council, VR (Grant No 2021-03265). The main funding body of The Swedish CArdioPulmonary bioImage Study (SCAPIS) is the Swedish Heart-Lung Foundation. The study is also funded by the Knut and Alice Wallenberg Foundation, the Swedish Research Council and VINNOVA (Sweden’s Innovation agency) the University of Gothenburg and Sahlgrenska University Hospital, Karolinska Institutet and Stockholm County council, Linköping University and University Hospital, Lund University and Skåne University Hospital, Umeå University and University Hospital, Uppsala University and University Hospital.; Funding text 2: Per Wollmer reports grants from Swedish Heart and Lung foundation, grants from EuroNanomed II, grants from Swedish Innovation Agency, grants from Swedish Research Council, during the conduct of the study; personal fees from GlaxoSmithKline, personal fees from Chiesi Pharma, outside the submitted work; In addition, Professor Per Wollmer has a patent Device and method for pulmonary function measurement issued; Jakob Löndahl reports grants from Swedish Heart and Lung foundation, grants from Swedish Research Council for Health, Working Life and Welfare, grants from Swedish Research Council for Environmental, Agricultural Sciences and Spatial Planning, FORMAS, during the conduct of the study; In addition, Jakob Löndahl has a patent Device and Method for pulmonary function measurement issued. The other authors declare no competing interests.
2022-08-012022-08-012023-05-22Bibliographically approved